Neuroendocrine neoplasia goes molecular — time for a change

Guido Rindi, Bertram Wiedenmann

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.

Original languageEnglish
JournalNature Reviews Clinical Oncology
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Neoplasms
Cohort Studies
Sensitivity and Specificity

ASJC Scopus subject areas

  • Oncology

Cite this

Neuroendocrine neoplasia goes molecular — time for a change. / Rindi, Guido; Wiedenmann, Bertram.

In: Nature Reviews Clinical Oncology, 01.01.2018.

Research output: Contribution to journalArticle

@article{0e08a528f16f48a2a5c834fe2478efd5,
title = "Neuroendocrine neoplasia goes molecular — time for a change",
abstract = "In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.",
author = "Guido Rindi and Bertram Wiedenmann",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/s41571-018-0118-8",
language = "English",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Neuroendocrine neoplasia goes molecular — time for a change

AU - Rindi, Guido

AU - Wiedenmann, Bertram

PY - 2018/1/1

Y1 - 2018/1/1

N2 - In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.

AB - In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.

UR - http://www.scopus.com/inward/record.url?scp=85056124055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056124055&partnerID=8YFLogxK

U2 - 10.1038/s41571-018-0118-8

DO - 10.1038/s41571-018-0118-8

M3 - Article

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

ER -